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Objective: Open repair for acute type B dissection with malperfusion is associated with significant morbidity.
Thoracic aortic endovascular repair has been proposed as a less-invasive therapy for acute type B dissection
with malperfusion. Benefits of thoracic aortic endovascular repair include the potential for false lumen thrombo-
sis. Its risks include both early morbidity and mortality, and uncertain late results with potentially unstable landing
zones. We present the first long-term analysis of an alternative endovascular approach consisting of percutaneous
flap fenestration with true lumen and branch vessel stenting to restore end-organ perfusion.
Methods: Outcomes were analyzed for 69 patients presenting with acute type B dissection with malperfusion
from 1997 to 2008. All patients were evaluated with angiography and treated with a combination of flap fenes-
tration, true lumen, or branch vessel stenting where appropriate.
Results:Mean age was 57.3 years. Identified malperfused vascular beds included spinal cord (5), mesenteric (40),
renal (51), and lower extremity (47). Major morbidity included dialysis need (11), stroke (3), paralysis (2), and 30-
day mortality (n ¼ 12, 17.4%). Mean Kaplan–Meier survival was 84.3 months. Although late mortality was as-
sociated with age (P<.0001), neither the type nor the number of malperfused vascular beds correlated with vital
status at last follow-up (P> .4). Freedom from aortic rupture or open repair at 1, 5, and 8 years was 80.2%,
67.7%, and 54.2%, respectively.
Conclusion: Presentation with acute type B dissection with malperfusion carries a significant risk for both early
and late mortality. Percutaneous approaches allow for rapid restoration of end-organ perfusion with acceptable
results. These long-term results can serve as comparative data by which to evaluate newer therapies for acute
type B dissection with malperfusion, such as thoracic aortic endovascular repair.In the management of acute type B dissection (B-AD), oper-
ative therapy has assumed a secondary role and is usually
reserved for complications arising from the initial insult.1
Malperfusion from branch vessel compromise in acute
type B dissection (B-MP), a highly morbid complication,
results in end-organ dysfunction and limits survival.2,3
This indication for operation has been associated with
a high risk for major morbidity and mortality.4
The role of an endoluminal approach has been growing in
response to a perceived need to reduce postoperative mor-
bidity.5-12 With the successful application of endograft ther-
apy for thoracic aortic aneurysm repair (TEVAR), several
investigators have described its use in B-MP to alleviate
end-organ ischemia.8-10 Before the reported application of
TEVAR for B-MP, we and others described an alternative
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doi:10.1016/j.jtcvs.2009.01.037300 The Journal of Thoracic and Cardiovascular Suapproach to relieve end-organ ischemia without the need
for open aortic resection or fenestration, to avoid the report-
edly high rates of morbidity and mortality with these proce-
dures. In this percutaneous technique, the dissection flap is
fenestrated, and the aortic true lumen is then stented open
to prevent dynamic collapse onto the origin of the branch
vessel.6,7 Branch vessel stenting is then performed for asso-
ciated continued static obstruction. The purpose of the
current report is to describe the long-term outcomes of this
endovascular approach in the treatment of malperfusion in
B-AD and provide objective data so that suitable compara-
tive analyses may be conducted for newer therapies, such
as TEVAR.
MATERIALS AND METHODS
This study was approved by the institutional review board of the Univer-
sity of Michigan Hospitals (institutional review board study 2003-0128).
Informed consent requirements were waived for this study.
Data from all patients admitted to the University of Michigan Hospitals
between 1997 and 2008 with a diagnosis of B-MP were prospectively col-
lected and retrospectively analyzed. B-AD for this study was defined as its
occurrence within 14 days of presentation to the hospital and with pathology
confined to the thoracoabdominal aorta distal to the left subclavian artery.
Diagnosis of B-AD was made by the combination of clinical factors,
including history and physical examination, and either the use of dynamic
computed tomography (CT) or transesophageal echocardiography. A com-
bination of clinic and hospital records, imaging studies, and query of thergery c August 2009
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B-AD ¼ acute type B dissection
B-MP ¼ acute type B dissection with
malperfusion
CT ¼ computed tomography
TEVAR ¼ thoracic aortic aneurysm repair
National Death Index was used to obtain in-hospital and long-term informa-
tion. Follow-up was 100% complete at a mean of 41.9 months (median 37.4
months).
The primary therapy for B-AD at the University of Michigan is medical
therapy to reduce cardiac contractile force and blood pressure management
to maintain systolic blood pressure less than 120 mm Hg. Patients who pre-
sented with evidence of end-organ ischemia (ie, abdominal pain or tender-
ness, lactic acidosis, hyperamylasemia, abnormal transaminases, elevated
creatinine or reduced urine output, pulse deficit with or without sensorimo-
tor changes, or evidence of paraplegia) proceeded to angiography. Those
patients who also had evidence of complete true lumen collapse or CT
evidence of bowel or renal malperfusion without clinical evidence of end-
organ dysfunction were also sent for angiography. An aggressive stance was
deemed appropriate in this latter group to avoid the delay from onset of
known angiographic malperfusion to clinical sequelae. In the application
of these criteria, 105 patients underwent angiography to evaluate for
B-MP. After excluding those patients without angiographic evidence of
branch vessel compromise, as well as those in whom angiography was un-
dertaken after open aortic repair, a subset of 69 patients was identified as the
target cohort for analysis. This group completed diagnostic angiography and
intervention at a median of 1 day after presentation. Clinical evidence of
malperfusion was suspected in all but 2 patients who underwent study pre-
dominantly for radiographic findings. Marked true lumen collapse (new
finding) was identified in both patients on standard follow-up CT scans
obtained at 1 week after initial presentation, and this prompted referral for
angiography.
The angiographic evaluation for malperfusion is entirely a percutaneous
method and has been described in detail.6,13When branch vessel obstruction
is present, the first priority is to reperfuse the mesenteric vessels first, fol-
lowed by renal and limb revascularization. When dynamic obstruction of
the branch vessels is present, flap fenestration to create a large reentry
tear is performed. Although fenestration can equalize pressures across the
dissection flap, self-expanding 16- to 22-mm diameter Wallstents
(Schneider, Minneapolis MN) are usually placed to buttress open the aortic
true lumen and are typically placed near the compromised branch vessel.
Fenestration and stenting of the aortic true lumen treat the dynamic obstruc-
tion of branch vessels but not the static obstruction if also present. The latter
is determined by identifying a significant (20 mm Hg) systolic gradient
from the aorta to the branch vessel. The true lumen of the artery that is com-
promised by a static obstruction is cannulated and treated with a self-ex-
panding stent to relieve the obstruction. Completion manometry confirms
adequate perfusion. It is important to note that the procedure is primarily
based on the use of intravascular ultrasound and manometry and that dye
load is minimized to prevent renal injury (usually<50 mL). This is primar-
ily accomplished by using hand injections of contrast material for confirma-
tion of catheter placement in branch vessels to obtain manometric
measurements and avoidance of high-volume aortography.
Postoperative management after intervention in all patients consisted of
aspirin therapy and standard management of blood pressure and end-organ
dysfunction. When spinal cord ischemia was present, cerebrospinal fluid
drainage was instituted before angiographic study and maintained for at
least 48 hours after the procedure. All patients were then imaged before dis-
charge from the hospital to evaluate the aorta. Standard imaging protocols
for follow-up after discharge include obtaining CT scans at 1 month,The Journal of Thoracic and C3 months, and annually thereafter. Indications for aortic repair during the
chronic phase include 1) presence of symptoms; 2) presence of a re-dissec-
tion, or 3) growth rate of more than 1 cm/y, or an absolute diameter greater
than 5.5 to 6 cm in asymptomatic patients. Our imaging follow-up was in-
complete with 15 patients (21%) receiving no imaging after discharge.
Statistical Analysis
Early outcomes included rates of mortality, stroke, renal failure needing
dialysis, and spinal cord ischemia. The primary late outcomes of interest
were vital status with survival time. Early mortality was defined as that oc-
curring within 30 days of admission or in-hospital death. Late mortality was
defined as that occurring thereafter.
Data were analyzed using the Statistical Package for the Social Sciences
(SPSS Inc., Chicago IL).All data are expressed asmean standarddeviation
where applicable. Dichotomous variables were evaluated using chi-square
analysis, and continuous variables were evaluated using 1-way analysis of
variance. Multivariate models (binary logistic regression) were constructed
using a backward conditional process to identify factors that were indepen-
dently associated with each of the outcomes of interest. The factors used in
multivariate analysis included using those with P  .1 significance on uni-
variate analysis. Survival analysis was analyzed by Kaplan–Meier methods.
RESULTS
Sixty-nine patients were found to have evidence of mal-
perfusion on angiography. Demographics and comorbidities
of this group are listed in Table 1. The patterns of malperfu-
sion in this cohort are also listed in Table 1 and include both
clinical presentation findings and those obtained on angiog-
raphy. The majority of patients had involvement of multiple
beds on angiography (69.6%). The distribution of involved
arterial beds is also listed in Table 1. There were 3 treatment
options in the cohort. The therapy in all patients involved
various combinations of these 3 options based on the find-
ings on arteriography (Figure 1, Table 1). This resulted in
complete angiographic reperfusion in all patients except 5.
Two of these patients had spinal cord symptoms only and
presented with a thrombosed false lumen. One patient had
cord ischemia and a transceliac artery gradient of 43 mm
Hg and was not treated because of a large patent superior
mesenteric artery supplying hepatic flow. The remaining 2
patients had renal malperfusion, and technical issues pre-
vented successful therapy.
When accounting for 185 malperfused vascular beds
(identifying each kidney and limb as separate beds), the
overall technical success rate for flow restoration was
95.7%. In 5 patients who all had renal malperfusion, techni-
cal issues prevented placement of branch stents. Another
patient with right renal and mesenteric malperfusion had
intramural hematoma causing a gradient in the kidney.
This was left untreated because his overall clinical condition
required prolonged efforts to restore mesenteric perfusion
withmechanical thrombolysis and flap fenestration. On a fol-
low-up CT scan, the renal artery intramural hematoma had
resolved. One patient who presented with malperfusion of
his right kidney, superior mesenteric artery, and both limbs
was noted to have a thrombosed infrarenal aortoiliac graft.
Visceral and renal perfusion were restored with fenestration.ardiovascular Surgery c Volume 138, Number 2 301
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thrombolysis before performance of a femoral–femoral
crossover graft and fasciotomies. Finally, in 1 patient, the ce-
liac artery was not treated for reasons noted above.
Early Results
The median length of stay was 11 days. Early mortality
was seen in 12 patients (17.4%). By univariate analysis,
TABLE 1. Demographics, comorbidities, and presentation patterns
Variable Frequency (n ¼ 69)
Demographics
Mean age (y) 57.3  12.1
Male sex 54 (78.2%)
Coronary artery disease 9 (13.0%)
Myocardial infarction 6 (8.7%)
Hypertension 57 (82.6%)
Diabetes mellitus 9 (13.0%)
Chronic obstructive pulmonary disease 11 (15.9%)
Peripheral vascular disease 10 (14.5%)
Stroke 6 (8.7%)
Renal insufficiency 5 (7.2%)
Creatinine on admission (mg/dL) 1.7  1.1
Marfan syndrome 3 (4.3%)
Clinical findings of malperfusion* No. affected*
Spinal cord ischemia 5
Mesenteric malperfusion
Acute abdomen 5
Hematochezia or hematemesis 2
Acidosis, elevated transaminases, amylase, or
lipase
6
Severe abdominal pain, nausea, or vomiting 10
Renal malperfusion
Elevated creatinine 19
Oliguria/anuria 5
Refractory hypertension 6
Limb malperfusion
Loss of pulses or sensorimotor changes 26
Angiographic findings No. affected
Affected vascular beds on angiography
Spinal cord 5 (7.2%)
Mesenteric 40 (58.0%)
Renal 51 (73.9%)
Limb 47 (68.1%)
No. of affected vascular beds on angiography
1 21 (30.4%)
2 23 (33.3%)
3 25 (36.2%)
Type of percutaneous intervention
Flap fenestration alone 4
Flap fenestration and true lumen stenting 16
Flap fenestration, true lumen, and branch vessel
stenting
23
Flap fenestration and branch vessel stenting 5
True lumen and branch vessel stenting 3
Branch vessel stenting alone 13
*More than 1 may be present per patient.302 The Journal of Thoracic and Cardiovascular Suronly increased age correlated with early mortality (mean
age of 55.5 years for survivors vs 65.8 years for expired
patients, P ¼ .006). Correlative trends were seen in those
presenting with a history of peripheral vascular disease
(P ¼ .067) and those who required dialysis (P ¼ .07).
Neither the number nor the type of malperfused vascular
beds correlated with early mortality (all P  .5). The causes
of early mortality and the corresponding clinical scenarios
are listed in Table 2. Aortic rupture was the identified cause
of death in 5 patients. Although the site of fenestration in
all patients was intraabdominal, and the site of rupture in all
was intrathoracic, the procedure cannot be excluded as a con-
tributing factor for rupture. Finally, there were no instances
of retrograde type A dissection related to the procedure.
Major morbidity included stroke, which occurred in 3 pa-
tients (4.3%). Two patients who presented with poorly con-
trolled hypertension sustained strokes in watershed regions
likely secondary to overly aggressive antihypertensive ther-
apy. The remaining patient had a procedurally related event
and an expressive aphasia with near complete resolution
1 month after discharge. Dialysis was required in 10 patients
(14.5%), and renal function recovered in all but 3 who died
of multisystem organ failure related to their malperfusion
syndrome. Finally, the incidence of permanent spinal cord
ischemia in this cohort was 2.9% (n ¼ 2 patients). Both of
these patients presented initially with paraplegia from their
acute dissection.
To generate a sufficient event rate for analysis, a compos-
ite end point of adverse events was constructed to include
in-hospital or 30-day mortality, need for dialysis, and occur-
rence of stroke or spinal cord ischemia. Univariate binary
variables correlating with this end point included a history
of peripheral vascular disease (P ¼ .05) or renal insuffi-
ciency (P ¼ .02), the occurrence of limb malperfusion
(P¼ .02), or the presence of 3 or more malperfused vascular
beds (P ¼ .05). The only continuous variable correlating
with occurrence of composite outcome was an elevated ad-
mission creatinine (2.3 1.4 vs no occurrence of composite
outcome 1.3 0.6, P<.0001). The only predictive variables
of a poor outcome onmultivariate analysis were the presence
of peripheral vascular disease (P¼ .028), an elevated admis-
sion creatinine (P¼ .005), and the presence of limb malper-
fusion (P ¼ .015).
Late Results
In this cohort, the overall crude all-cause mortality rate at
last follow-up was 36.2% (n ¼ 25). The actuarial survival
curve is shown in Figure 2, identifying a mean survival of
84.3 months. By univariate analysis, only increased age cor-
related with late mortality (mean age of 53.4 years for survi-
vors vs 64.4 years for expired patients, P< .0001). By
Kaplan–Meier analysis, there were no time-dependent ef-
fects of different malperfused beds on late survival (all
beds P > .5). Fourteen patients sustained aortic rupturegery c August 2009
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an outside institution and transferred after a diagnosis of B-AD. After transfer, he was noted to have mild abdominal discomfort. CT scan suggested near total
aortic true lumen collapse in the proximal descending aorta (A), with suggestion of a dynamically compromised celiac artery origin (B), and a collapsed true
lumen and dissection flap within the superior mesenteric artery (SMA), suggesting both dynamic and static obstruction of this vessel (C). On angiographic
evaluation, he was found to have a dissection flap extending into the SMA with an aorto-mesenteric gradient of 43 mm Hg (D). He was also noted on in-
travascular ultrasound to have dynamic compromise of the celiac, superior mesenteric, and right renal artery origins. He underwent aortoplasty (fenestration)
and true lumen stenting at the level of the celiac artery, which resolved all gradients except that seen in his SMA. He subsequently underwent placement of
a stent into the SMA branch directly with complete resolution of the aorto-mesenteric gradient. Follow-up imaging at 1 month shows a patent fenestration tear
in the dissection flap (E) and a patent stent in the SMA itself (F).The Journal of Thoracic and Cardiovascular Surgery c Volume 138, Number 2 303
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Patient
age (y) Presenting symptoms
Affected
vascular beds Intervention Cause of mortality
51 Lower-extremity
sensorimotor changes
Renal, mesenteric,
limb
Fenestration, true lumen stenting, SMA angioplasty,
thrombolysis of prior infrarenal aortic tube graft
Multisystem organ failure*
56 Limb ischemia,
progressive acidosis
Mesenteric, limb Fenestration, true lumen stenting Multisystem organ failure
53 Acute abdomen Renal, mesenteric Stenting of SMA, celiac axis, left renal, and aortoiliac
vessels
Multisystem organ failure*
51 Acute abdomen Renal, mesenteric,
limb
Fenestration, true lumen stenting, SMA, celiac and left
renal arterial stenting
Multisystem organ failure
61 Acute abdomen Renal, mesenteric Fenestration, SMA and celiac axis stenting Watershed infarct in patient
with history of multiple strokes*
71 Limb sensorimotor
changes
Limb Fenestration False lumen rupture on
post-procedure day 2
76 Limb sensorimotor
changes
Renal, limb Fenestration, aortoiliac stenting False lumen rupture on
post-procedure day 4
74 Elevated creatinine Renal, limb Fenestration, aortoiliac stenting, renal artery stenting,
and suction embolectomy
False lumen rupture on
post-procedure day 7
67 Acidosis, cadaveric limbs,
obtundation
Renal, mesenteric,
limb
Fenestration, aortoiliac and SMA stenting Multisystem organ failure
85 Noted extension of
dissection on
follow-up imaging
Renal Fenestration, renal artery stenting False lumen rupture on
post-procedure day 2
71 Infrarenal aortic thrombosis,
cadaveric legs
Renal, mesenteric,
limb
True lumen stenting Multiorgan failure after
recurrent aortic thrombosis
74 Cadaveric limbs Renal, mesenteric,
limb
Fenestration, true lumen stenting, mechanical
thrombolysis of prior aortoiliac graft
False lumen rupture on
post-procedure day 5
SMA, Superior mesenteric artery. *Care withdrawn at the request of family.(n ¼ 5, all in-hospital) or need for aortic resection (n ¼ 9)
during follow-up. Kaplan–Meier analysis of freedom from
aortic rupture or need for aortic repair is shown in Figure 3.
This demonstrates a mean time to rupture or need for repair
of 79.2 months.
DISCUSSION
The pathophysiology of malperfusion in B-AD consists
principally of both dynamic and static obstruction of the in-
volved branch vessel.6,13 In static obstruction, the dissection
flap enters the branch vessel with absent or inadequate distal
reentry and causes ischemia by reducing the true lumen
diameter. In contrast, the dissection flap in dynamic ob-
struction intermittently prolapses across the orifice of the
branch vessel during the cardiac cycle, and this subse-
quently results in end-organ ischemia. In addition to
traditional clinical criteria demonstrating evidence of end-
organ ischemia, the diagnosis of malperfusion also rests
on the manometric or angiographic demonstration of ongo-
ing anatomic branch artery obstruction. It should be noted
that the clinical diagnosis of malperfusion, based for exam-
ple on newly diagnosed renal insufficiency, cannot distin-
guish acute renal injury caused by transient but resolved
renal artery obstruction from that caused by ongoing me-
chanical obstruction.304 The Journal of Thoracic and Cardiovascular SuRecent studies have suggested that B-AD carries an in-
hospital mortality rate of 10% to 15%.1,2 The International
Registry of Acute Dissection consortium identified the
presence of branch vessel compromise as an important
FIGURE 2. Kaplan–Meier analysis of survival after presentation with
B-MP. This figure demonstrates that patients presenting with B-AD have a
dismal prognosis with 1-, 5-, and 8-year survivals of 76.2%, 63.5%, and
55.3%, respectively. The overall mortality rate in this entire cohort was
36.2% at a mean follow-up of 41.9 months.rgery c August 2009
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in the setting of malperfusion consists of open repair of the
aorta by resection of the primary entry tear, direct bypass
grafting of the involved branch vessels, or creation of a fen-
estration in the abdominal aorta.1,3-5 However, results with
operative therapy for B-AD have been dismal, with early
mortality rates approaching 40%.1-5,14
It was in this setting that we and others described an endo-
vascular solution to relieve end-organ ischemia from branch
vessel compromise as a possible means to improve early out-
comes.6,7 In this approach, dynamic obstruction is relieved
by percutaneously creating a flap fenestration to generate
a large reentry tear. The true lumen is then stented open in
the region of the involved branch to alleviate the dynamic
obstruction. For static obstruction, the endovascular ap-
proach consists of placement of stents into the target vessel.
Thoracic endografting has been proposed as an alternative
solution to open repair or percutaneous fenestration as
a means to resolve B-AD.8-12,15 With this approach, the en-
try tear is sealed by TEVAR, and the dynamic obstruction is
then relieved. Associated static obstruction is not treated by
TEVAR and requires open revascularization or branch ves-
sel stenting. Benefits of TEVAR in this setting include pro-
moting thrombosis of the false lumen with subsequent
beneficial aortic remodeling.15 This would be of significant
benefit in alleviating the inherently increased risk for rupture
present in those patients presenting with an acute dissection
with ectatic or frankly aneurysmal aortic dimensions.16 The
demonstration of beneficial aortic remodeling after TEVAR
for B-AD was first defined in landmark studies by Dake and
colleagues.8 Although early results of TEVAR have sug-
gested efficacy, no study to date describes the long-term out-
comes with this approach on aortic growth rates. Szeto and
colleagues,17 from the University of Pennsylvania, de-
FIGURE 3. Actuarial freedom from aortic repair or rupture. This Kaplan–
Meier analysis suggests that the 1-, 5-, and 8-year freedoms from operative
repair or aortic rupture are 80.2%, 67.7%, and 54.2%, respectively.The Journal of Thoracic andscribed the use of TEVAR for B-MP in 17 patients. They re-
ported a 0% operative mortality and a 94% 1-year survival.
However, long-term data in that study were lacking, and the
incidence of neurologic complications in the entire series of
complicated type B dissection (n ¼ 35) exceeded 10%. In
another recent intermediate-term analysis, complete throm-
bosis of the false lumen was achieved in only 64.7% of acute
type IIIb dissections.11 An additional theoretic concern for
long-term success with the use of TEVAR for B-AD is
that the landing zone(s) may be unstable if they exist in dis-
sected aorta. Sizing the aorta for correct endograft selection
can also be problematic, particularly in the distal portion of
the repair, because the dissected aorta will continue to re-
model. A rare but often malignant complication of TEVAR
in B-AD is the occurrence in 2% to 4% of patients of a ret-
rograde dissection into the ascending aorta with its cata-
strophic sequelae.12,15 This lethal complication was not
seen in our series of percutaneous fenestration. Finally, in
performing TEVAR, there is a concern for spinal cord ische-
mia with intercostal artery coverage, particularly if the left
subclavian artery requires exclusion.8-12,15 This latter con-
cern is eliminated with percutaneous fenestration tech-
niques, because there is no inherent loss of intercostal
arteries in contrast with TEVAR. Indeed, given the high
rates of neurologic morbidity seen with TEVAR for acute
dissection, this may be a most important advantage of percu-
taneous fenestration over TEVAR.17
The current study describes late outcomes for one of the
largest cohorts of B-AD presenting with malperfusion syn-
drome. The early mortality seen in our series suggests that
the fenestration procedure has significantly reduced early
mortality when compared with open surgery and is similar
to that reported in other series of uncomplicated type B dis-
section.2 However, the major weakness of a percutaneous
fenestration approach extends from its inability to allow
for favorable aortic remodeling after the procedure. By cre-
ating a large reentry tear, flow is ensured within the false
lumen, thus precluding its thrombosis. In essence, what is
created by the percutaneous fenestration approach is an an-
atomic conversion from a complicated dissection to an un-
complicated one, whereby the branch vessel compromise
and not the aorta per se is treated. This allows for the patient
to recover from the effects of the malperfusion syndrome
without the associated morbidity of an open aortic repair
in this setting. Presumably, however, if an indication for aor-
tic repair exists on the basis of aortic dimension, it can then
be done in a more elective and controlled fashion after reso-
lution of the malperfusion syndrome. An important limita-
tion of this approach (in contrast with open surgery or
TEVAR) is its inability to treat the risk for aortic rupture.
In our series, 5 patients (7.2%) sustained aortic rupture.
Although the site for fenestration was intraabdominal, and
the site of rupture in all was thoracic, it is possible that hemo-
dynamic alterations after fenestration contributed to rupture.Cardiovascular Surgery c Volume 138, Number 2 305
Acquired Cardiovascular Disease Patel et al
A
C
DA TEVAR approach in this situation may have eliminated
the risk for rupture. It is unclear, however, whether this
benefit of TEVAR outweighs its reported risk of paraplegia
or retrograde dissection, neither of which was observed with
the percutaneous fenestration approach in our series.
Study Limitations
Limitations of this study include its retrospective nature
and lack of comparison group (eg, open repair, TEVAR,
or open fenestration groups). In addition, although this study
describes outcomes for treatment of one of the largest series
of patients with B-MP, the sample size is relatively small. Fi-
nally, although the follow-up for the primary end point of
mortality is complete, there is incomplete imaging follow-
up (21% without postdischarge imaging).
Our current approach at the University of Michigan is
based on risk stratification to determine the most suitable op-
tion. We elect to perform fenestration and stenting for those
patients with small total aortic diameters presenting with
malperfusion. If the patient is young but presents with an
aortic diameter greater than 5 cm, we will initially attempt
to resolve the malperfusion with fenestration and stenting
and then subsequently treat the aneurysm with an open ap-
proach within several weeks of presentation. TEVAR is re-
served for those presenting with malperfusion who are older
(70 years) and have total aortic diameters greater than 4.5
to 5 cm or those presenting with the complication of rupture
in association with malperfusion.
CONCLUSIONS
We have described the late results of a percutaneous-
based approach for the treatment of peripheral ischemic
complications resulting from B-AD. In contrast with data re-
ported from open repair, these long-term data may serve as
a more suitable comparison against which to evaluate
TEVAR as a primary therapeutic modality for this lethal
disease.
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Discussion
Eric Roselli, MD (Cleveland, Ohio). Congratulations on a fine
presentation and an outstanding experience. Dr Patel and I did some
of our endovascular training together under the leadership of Roy
Greenberg, who apologizes for not being here today, but he and I
reviewed the article together and compiled the following questions
and observations.
Dr Patel and colleagues at the University of Michigan have pro-
vided us with a relatively large amount of long-term data regarding
a technique used to treat malperfusion syndrome after acute distal
dissection. Dr Williams and his counterparts have long been con-
sidered the pioneers of these complex interventional techniques,
and their expertise in aortic flap fenestrations is likely unparalleled.
However, several fundamental questions are raised by both the im-
plementation of such a treatment strategy and the extended follow-
up data you have provided.
Would you please clarify your patient population? Malperfusion
is really a clinical syndrome rather than a radiographic diagnosis,
yet in your series you included patients with a clinical syndrome
and evidence of true lumen collapse by computed axial tomography
scan. Can you segregate your results to provide us with the number
of patients treated solely on the basis of radiographic evidence of
true lumen collapse or ischemia versus those with clinical evidence
of this complication along with their respective outcomes?
Dr Patel. You are absolutely correct in that there is a difference
between radiographic findings and presentation with a syndrome of
end-organ dysfunction. We completely agree with that. The latter,
the syndrome of end-organ dysfunction, results from prolonged is-
chemia, and at our center, because of the availability of these inter-
ventional techniques, we have taken an aggressive stance in
studying patients who present with angiographic or CT findings
to prevent the subsequent development of end-organ failure from
prolonged ischemia.rgery c August 2009
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statistical difference in outcomes, and this was likely secondary
to the small sample size in the group that was studied only for an-
giographic findings.
Dr Roselli. Very good. The 2 therapies principally used to
treat malperfusion after acute aortic dissection remain endovascu-
lar grafting and aortic flap fenestration, as you clearly described to
us in the beginning of your talk. We have used both techniques;
however, the pendulum has recently swung strongly in the direc-
tion of stent-graft therapy. Although some of this may relate to
the relative simplicity of endovascular grafting over the flap fen-
estration, I believe that much of this has to do with the treatment
objectives.
The rationale for stent-graft therapy is that covering the primary
fenestration markedly decreases false lumen inflow, allowing the
false lumen to passively decompress. We have found that perfusion
of the mesenteric vessels, lower extremities, and renal branches are
almost always restored via this technique once we reestablish true
lumen flow, and it is exceedingly rare that we have to stent the
branch vessels. In addition, the use of these stent grafts promotes
false lumen thrombosis and in the region of the treatment may pro-
mote aortic remodeling. In contrast, aortic flap fenestration allows
flow through a widened fenestration and equalization through the 2
lumens, which may increase the likelihood of static compression, at
least in our experience.
Howmany arteries in your series required flap fenestration in ad-
dition to branch stenting, and were the outcomes different in those
patients?
Dr Patel. Eric, again, you are correct in that by excluding false
lumen flow with TEVAR, you may resolve the associated static ob-
struction by decompressing the false lumen. I at present do not have
the number of arteries that required branch vessel stents in our co-
hort, but I can tell you that in our analysis, we did find that 43 of the
69 patients required branch vessel stents. We do agree that the point
you raise is an important one, and we will have to construct that
analysis to allow for a suitable comparison of both TEVAR and
this approach.
Dr Roselli. I have one last question. It was a little disconcerting
to us that in this large landmark series only 15 of the 69 patients
were available at 2 years for, presumably, imaging studies, that
is, in your second analysis in which you looked at freedom from re-
operation and rupture. We share your view that once a patient has
a dissection, he/she should become your patient for life, and all of
the procedures that are performed should be done in the context of
anticipating a later repair. You described 5 early ruptures and 14 pa-
tients with late rupture or reoperation, for a rate of more than 20%.
Do you think that the rate of significant growth of these aortas was
even higher and that some of these patients were not deemed oper-
ative candidates? Also in this subgroup of patients, did you look to
see if there were any other factors such as an initial aortic diameter
of more than 4 cm or a false lumen diameter more than 22 mm, and
if so, should those patients have been treated with stent grafting in
addition to fenestration and branch grafting?
Dr Patel. You are correct in stating a major limitation of our re-
sults. I think the point that we would like to make is that when we
undertook this analysis, at the time when this procedure was really
started, there was no ability to provide thoracic endografting for pa-
tients with acute type B dissection. The goal of the therapy when itThe Journal of Thoracic and Cwas first started was to restore the branch vessel perfusion and per-
haps restore the survival curve toward that seen with uncomplicated
dissection.
You are absolutely right that the limitations of the article are
such that we do not have complete imaging follow-up in this co-
hort. What we did find when we accounted for all of this was that
the survival analysis suggested that the mean time to open repair or
rupture was 79 months. We did not specifically look at aortic or
false lumen diameters in this study. Whether the results we show
are good or not, I am not sure, but we do believe that they are better
than the results for open surgical series that have been reported and,
as well, medical therapy for type B dissection presenting with is-
chemia. We therefore believe that the report we have proposed
should be considered a better benchmark study for evaluation of
newer therapies, such as TEVAR.
At our institution, we wholeheartedly believe in the thoracic en-
dovascular approach in this setting, and I think there are certain ad-
vantages for TEVAR that we suspect are likely not present with the
fenestration and stenting approach. However, as we move forward
and more and more groups describe outcomes with endovascular
repair for ischemic type B dissections, I think rather than comparing
them with open repair, which has a known dismal prognosis, this
report would probably be a more suitable comparison.
D. Craig Miller, MD (Stanford, Calif). Be careful what you
wish for, Dr Patel, because the data are already out there. I wasn’t
going to get up until I heard you say that you use these results as
a benchmark for thoracic aortic stent-grafting. I am sorry, but this
is very old flap fenestration and a true lumen stenting approach
can’t compete. We explored ‘‘fen-stent’’ for complications of acute
and chronic aortic dissection in the late 1980s and early 1990s but
abandoned it for the most part when we started thoracic aortic
stent-grafting in 1992, except when used as an adjunct after stent
grafting.
An article published in 1999 with our colleagues at Mie Univer-
sity, Japan, included only 29 patients, certainly not a big number,
but as Eric just said, let’s carefully define the substrate we are talk-
ing about. These were very sick people with complicated acute type
B dissections who were malperfused and basically dying in front of
us. Our initial goal was simply patient salvage. There were some
early deaths; we got caught, just like you have in Michigan, by try-
ing even though irreversible end-organ damage had already oc-
curred, or something Dr Shumway likened to ‘‘doing warm
autopsies.’’ We try to avoid this pitfall, but it is nearly impossible
to knowwho is salvageable and who is not with certainty. Now, just
including patients with Stanford complicated acute type B aortic
dissection, we have 16 who underwent emergency thoracic aortic
stent-grafting who have been followed for 5 years; follow-up com-
pleteness was 100%. After the initial 25þor –11% early mortality,
there were no additional deaths. The 5-year actuarial survival esti-
mate was 73þor –11% (Verhoye JP, Miller DC, Sze D, Dake MD,
Mitchell RS. Complicated acute type B aortic dissection: midterm
results of emergency endovascular stent-grafting. J Thorac
Cardiovasc Surg. 2008;136:424-30). Therefore, I submit this is
the first-generation stent-graft benchmark you were referring to
for comparison, not your results with ‘‘fen-stent.’’ Flap fenestration
and true lumen stenting for static obstruction are valuable adjuncts
after stent grafting but cannot compete as a primary first line of ther-
apy for acute aortic dissection today.ardiovascular Surgery c Volume 138, Number 2 307
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clusion slide you listed rupture and death, and you said both are
bad. Well, yes, death is usually pretty bad, but needing a late
open operation is not necessarily bad. Maybe that should be part
of our overall strategic goal, that is, do something quickly such
as a stent-graft to ameliorate the life-threatening lower-body mal-
perfusion, resuscitate the patients, and get them into better condi-
tion when an open thoracic or thoracoabdominal aortic operation
under more favorable conditions might proffer the optimal likeli-
hood of long-term survival. I don’t have any questions; I am just
issuing some words of caution.
Dr Patel. Just for the record, I will not compare myself with
you. But I do suggest that we agree that endovascular repair for
acute type B dissection is really here to stay, and we fully believe
in it. We have a different approach at Michigan. We suggest that
because of the unknown late results, we tend to perform thoracic
endografting in older patients. However, in younger patients, we
have been aggressive with fenestration and stenting. If they do re-
quire aorta repair for degeneration down the road, we do know308 The Journal of Thoracic and Cardiovascular Surfrom our series and others that elective open repair is associated
with acceptable early and late results. In essence what we are doing
with fenestration and stenting in younger patients is exactly what
you proposed, and that is converting a patient who is dying in front
of you into a more elective situation in which he/she is more sal-
vageable.
BruceW. Lytle,MD (Cleveland, Ohio). If I understand you cor-
rectly, however, today you would not choose to do this procedure.
Or if I misunderstood you and you would perform this procedure
rather than stenting, who would you do it for?
Dr Patel. We do still do this procedure. As I said, for patients
who are younger, we do not know the long-term results of TEVAR
in this setting. At our institution, if a younger patient presents with
acute type B dissection with malperfusion, then we will often re-
store the branch vessel perfusion with fenestration and stenting.
If the aorta subsequently degenerates, the patient will then often
receive open therapy. If the patient is older, then we are more
aggressive with performing an endograft approach to treat the mal-
perfusion syndrome.gery c August 2009
